Marek Trněný

25.8k total citations · 3 hit papers
326 papers, 7.0k citations indexed

About

Marek Trněný is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Marek Trněný has authored 326 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 252 papers in Pathology and Forensic Medicine, 149 papers in Genetics and 147 papers in Oncology. Recurrent topics in Marek Trněný's work include Lymphoma Diagnosis and Treatment (243 papers), Chronic Lymphocytic Leukemia Research (142 papers) and CAR-T cell therapy research (62 papers). Marek Trněný is often cited by papers focused on Lymphoma Diagnosis and Treatment (243 papers), Chronic Lymphocytic Leukemia Research (142 papers) and CAR-T cell therapy research (62 papers). Marek Trněný collaborates with scholars based in Czechia, United States and United Kingdom. Marek Trněný's co-authors include Devinder Gill, Craig H. Moskowitz, Norbert Schmitz, Nicolas Mounier, Ofer Shpilberg, David C. Linch, Josette Brière, Christian Gisselbrecht, Nicolas Ketterer and Dávid Ma and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marek Trněný

304 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

2010 1.1k citations Christian Gisselbrecht, Bertram Glaß et al. Journal of Clinical Oncology profile →
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

2017 461 citations Robert Marcus, Andrew Davies et al. profile →
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Marek Trněný

Since Specialization

Citations

This map shows the geographic impact of Marek Trněný's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Trněný with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Trněný more than expected).

Fields of papers citing papers by Marek Trněný

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Trněný. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Trněný. The network helps show where Marek Trněný may publish in the future.

Co-authorship network of co-authors of Marek Trněný

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Trněný. A scholar is included among the top collaborators of Marek Trněný based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Trněný. Marek Trněný is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors 2025 ·Cell Death Discovery ·(unknown), (unknown), Jir̆ı́ Petrák, (unknown), (unknown), Ladislav Anděra, (unknown), (unknown), Ondřej Havránek, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marie Hubálek Kalbáčová, (unknown), Marek Trněný, Pavel Klener	2
2	Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia 2025 ·Seminars in Hematology ·Shayna Sarosiek, (unknown), Andrew R. Branagan, Simone Ferrero, Jahanzaib Khwaja, Eva Kimby, Damien Roos‐Weil, Naohiro Sekiguchi, Marek Trněný, Shuhua Yi, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, Monique C. Minnema	0
3	Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia 2025 ·Seminars in Hematology ·Éric Durot, Jithma P. Abeykoon, Damien Roos‐Weil, (unknown), Charalampia Kyriakou, David F. Moreno, Stephen M. Ansell, Rebecca Auer, Xinxin Cao, Roger G. Owen, Shuhua Yi, Irene Dogliotti, Marek Trněný, Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Ranjana H. Advani	1
4	Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies 2024 ·Blood Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), Ladislav Anděra, (unknown), Adéla Berková, Zuzana Zemanová, (unknown), (unknown), (unknown), Eric Davis, Marek Trněný, Pavel Klener, Ondřej Havránek	2
5	Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B) 2024 ·Blood ·(unknown), Christian Schmidt, Marek Trněný, Eva Giné, Olivier Hermine, Anke Ohler, (unknown), (unknown), Eva Hoster, Christiane Pott, Martin Dreyling, Georg Heß	2
6	Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia 2024 ·Blood Advances ·David J. Kuter, Jiřı́ Mayer, (unknown), (unknown), Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Robert Bird, Jaromír Gumulec, Milan Košťál, Terry Gernsheimer, Waleed Ghanima, Ahmed Daak, Nichola Cooper	11
7	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. 2024 ·Journal of Clinical Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Rubén Fernández-Álvarez, Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	4
8	Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. 2024 ·Journal of Clinical Oncology ·Tycel Phillips, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Tomasz Wróbel, Fritz Offner, (unknown), James Relf, David Carlile, Ben Byrne, (unknown), Linda Lundberg, Michael Dickinson	7
9	IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY 2023 ·Hematological Oncology ·Franck Morschhauser, Katerina Hatzi, Georg Lenz, Alex F. Herrera, Christopher R. Flowers, Marek Trněný, John M. Burke, Jian Hou, Philipp B. Staber, Eliza A. Hawkes, Koji Izutsu, Steven Le Gouill, David Belada, Alessandra Tucci, (unknown), (unknown), Jamie Hirata, Chengkuo Lee, Yanwen Jiang, Fabrice Jardin	1
10	A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials 2023 ·SHILAP Revista de lepidopterología ·Lale Kostakoğlu, Maurizio Martelli, Laurie H. Sehn, Andrew Davies, Marek Trněný, Michael Herold, Umberto Vitolo, Wolfgang Hiddemann, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Şahin, Gila Sellam, Carol Ward, Anas Younes	1
11	Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy 2021 ·Blood ·Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Kathryn Humphrey, David Pérez-Callejo, Linda Lundberg, James Relf, (unknown), David Carlile, Emma Clark, Carmelo Carlo‐Stella	20
12	Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma 2019 ·Clinical Cancer Research ·Dana Průková, Ladislav Anděra, Zuzana Nahácka, (unknown), Michael Svatoň, Magdalena Klánová, Ondřej Havránek, J. Soukup, (unknown), Zuzana Zemanová, (unknown), Eva Pokorná, Karel Helman, Kristina Forsterová, (unknown), Petra Vočková, Adéla Berková, Eva Froňková, Marek Trněný, Pavel Klener	63
13	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy 2019 ·Clinical Cancer Research ·Magdalena Klánová, Mikkel Z. Oestergaard, Marek Trněný, Wolfgang Hiddemann, Robert Marcus, Laurie H. Sehn, Umberto Vitolo, Alexandra Bazeos, Valentin Goede, Harald Zeuner, Andrea Knapp, Deniz Şahin, (unknown), Christopher R. Bolen, Andrés F. Cardona, Christian Klein, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle‐Rowson	54
14	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial breakdown → 2018 ·Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell	455
15	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study 2017 ·Blood ·Radhakrishnan Ramchandren, Michelle A. Fanale, Antonio Rueda, Philippe Armand, Marek Trněný, Tatyana Feldman, Stephen M. Ansell, Mariano Provencio, Ulrich Jaeger, Jonathon B. Cohen, Kerry J. Savage, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo‐Doménech	22
16	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 2017 ·Leukemia & lymphoma ·Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Heß, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, (unknown), Jan Walewski, Francesco Zaja, Pier Luigi Zinzani	18
17	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma 2015 ·Clinical Cancer Research ·Magdalena Klánová, Ladislav Anděra, Jan Bražina, (unknown), (unknown), J. Soukup, Dana Průková, (unknown), Radek Jakša, Karel Helman, Petra Vočková, (unknown), Jan Molinský, (unknown), Md. Mahmudul Alam, Roman Kodet, Robert Pytlík, Marek Trněný, Pavel Klener	72
18	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era breakdown → 2010 ·Journal of Clinical Oncology ·Christian Gisselbrecht, Bertram Glaß, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg, Dávid Ma, Josette Brière, Craig H. Moskowitz, Norbert Schmitz	1117
19	High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience 2010 ·Multiple Sclerosis Journal ·Eva Krasulová, Marek Trněný, Tomáš Kozák, (unknown), David Pohlreich, David Kemlink, Petr Kobylka, Ivana Kovářová, (unknown), Eva Havrdová	67
20	New prognostic markers of chronic lymphocytic leukemia in theeveryday hematological practice. A multicenter analysis. 2009 ·Michael Doubek, (unknown), (unknown), Martin Brejcha, Zdeněk Pospı́šil, (unknown), Yvona Brychtová, Šárka Pospı́šilová, Petr Cetkovský, Marek Trněný, Jiřı́ Mayer	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact